title: Interleukin-15 expression is associated with malignant potential in colon cancer cells.
abstract: Interleukin 15 (IL-15 mRNA expression was detected in human colorectal cancer cells (Colo320, WiDr, TCO and DLD1) by the reverse transcriptase-polymerase chain reaction (RT-PCR). Only Colo320 and WiDr cells secreted IL-15 culture medium. With IL-15 treatment, all cell lines grew at a rate of 120-180% of that of nontreated cells. A binding assay with (125)I-labeled IL-15 showed binding activity to IL-15 in Colo320 (K(d): 0.098 nM) cells. IL-15 also reversed the growth inhibition caused by serum starvation in Colo320 cells. IL-15-induced cell growth in regular and serum-free media was abrogated by anti-IL-15 antibody treatment in Colo320 cells. Moreover, IL-15 treatment reduced doxorubicin-induced cytostasis and cytolysis in Colo320 cells by 50%. The invasion capacity of IL-15-treated Colo320 cells was 5.3 times that of untreated cells. Immunoblotting showed that IL-15-treated Colo320 cells exhibited downregulation of p21Waf1 and Bax, and upregulation of Bcl-2, phospho-AKT, MMP9/MMP2, and VEGF. Finally, immunostaining of human colon cancer revealed that 33 (70%) of 47 Dukes' C cases showed IL-15 expression in cancer cells, whereas only 16% of Dukes' B cases did (p < 0.0001). IL-15 may play important roles in cell proliferation, invasion, and metastasis of human colorectal cancer.
authors.affiliation: Department of Oncological Pathology, Cancer Center, Nara Medical University, Kashihara, Japan. cooninh@zb4.so-net.ne.jp
authors.forename: H
authors.initials: H
authors.lastname: Kuniyasu
authors.forename: N
authors.initials: N
authors.lastname: Oue
authors.forename: D
authors.initials: D
authors.lastname: Nakae
authors.forename: M
authors.initials: M
authors.lastname: Tsutsumi
authors.forename: A
authors.initials: A
authors.lastname: Denda
authors.forename: T
authors.initials: T
authors.lastname: Tsujiuchi
authors.forename: H
authors.initials: H
authors.lastname: Yokozaki
authors.forename: W
authors.initials: W
authors.lastname: Yasui
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001665:Binding Sites; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D016895:Culture Media, Serum-Free; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D004336:Drug Antagonism; D005786:Gene Expression Regulation / Q000187:drug effects; D019409:Interleukin-15 / Q000235:genetics* / Q000378:metabolism; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000032:analysis; D051381:Rats; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D016895:Culture Media, Serum-Free; D019409:Interleukin-15; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D004317:Doxorubicin